Analysts Actions: ALKS CELG HK ORCL S

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Alkermes ( ALKS) was downgraded at UBS to neutral from buy. Lack of catalysts in the first half of 2014 with limited upside in the near term, UBS said. $42 price target.

Boston Scientific ( BSX) was initiated with a hold rating at Benchmark. Valuation call, based on a $12 price target, Benchmark said.

Citigroup
( C) was downgraded at Deutsche Bank to hold from buy. Fixed-income flows will likely be hurt by Fed policy, Deutsche said.

Celgene (CELG) was upgraded at UBS to buy from neutral. Higher conviction on ability to deliver 26% EPS CAGR, UBS said. $200 price target.

CF Industries (CF) was upgraded at Goldman Sachs to neutral from sell. $232 price target. Company will likely return more cash to shareholders, Goldman said.

Caesars Entertainment (CZR) was initiated with a sell rating at TheStreet Ratings.

[Read: Apple, China Mobile Deal Done: Report]

Delphi Automotive (DLPH) was upgraded to buy at TheStreet Ratings.

Halcon (HK) was upgraded at Morgan Stanley to equal-weight. Valuation call, based on a $4 price target, Morgan Stanley said.

Hub Group (HUBG) was upgraded at Wells Fargo from underperform to market perform. Company is taking the right steps to turn begin turning the business around, Wells Fargo said.

JM Smucker (SJM) was downgraded at Wells Fargo from market perform to underperform. Coffee sales are slowing down, Wells Fargo said.

Jack in the Box (JACK) was upgraded at Wedbush from neutral to outperform. $60 price target. See upside for both the core business and Qdoba, Wedbush said.

Kohl's (KSS) was upgraded at Bank of America/Merrill Lynch from neutral to buy. $65 price target. Operating income growth should turn positive in 2014, BofA/Merrill said.

Morgan Stanley (MS) was downgraded at Deutsche Bank from buy to hold. Sector will be hurt by changes in Fed policy, Deutsche Bank said.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round